{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:02:00Z","timestamp":1791298920442,"version":"4.1.0"},"reference-count":52,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2006,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            There is a dearth of information on the pharmacodynamics of \u201ccolistin,\u201d despite its increasing use as a last line of defense for treatment of infections caused by multidrug-resistant gram-negative organisms. The antimicrobial activities of colistin and colistin methanesulfonate (CMS) were investigated by studying the time-kill kinetics of each against a type culture of\n            <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n            in cation-adjusted Mueller-Hinton broth. The appearance of colistin from CMS spiked at 8.0 and 32 mg\/liter was measured by high-performance liquid chromatography, which generated colistin concentration-time profiles. These concentration-time profiles were subsequently mimicked in other incubations, independent of CMS, by incrementally spiking colistin. When the cultures were spiked with CMS at either concentration, there was a substantial delay in the onset of the killing effect which was not evident until the concentrations of colistin generated from the hydrolysis of CMS had reached approximately 0.5 to 1 mg\/liter (i.e., \u223c0.5 to 1 times the MIC for colistin). The time course of the killing effect was similar when colistin was added incrementally to achieve the same colistin concentration-time course observed from the hydrolysis of CMS. Given that the killing kinetics of CMS can be accounted for by the appearance of colistin, CMS is an inactive prodrug of colistin with activity against\n            <jats:italic>P. aeruginosa<\/jats:italic>\n            . This is the first study to demonstrate the formation of colistin in microbiological media containing CMS and to demonstrate that CMS is an inactive prodrug of colistin. These findings have important implications for susceptibility testing involving \u201ccolistin,\u201d in particular, for MIC measurement and for microbiological assays and pharmacokinetic and pharmacodynamic studies.\n          <\/jats:p>","DOI":"10.1128\/aac.00035-06","type":"journal-article","created":{"date-parts":[[2006,5,24]],"date-time":"2006-05-24T21:13:58Z","timestamp":1148505238000},"page":"1953-1958","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":341,"title":["Colistin Methanesulfonate Is an Inactive Prodrug of Colistin against\n            <i>Pseudomonas aeruginosa<\/i>"],"prefix":"10.1128","volume":"50","author":[{"given":"Phillip J.","family":"Bergen","sequence":"first","affiliation":[{"name":"Facility for Anti-Infective Drug Development and Innovation, Victorian College of Pharmacy, Monash University, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[{"name":"Facility for Anti-Infective Drug Development and Innovation, Victorian College of Pharmacy, Monash University, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig R.","family":"Rayner","sequence":"additional","affiliation":[{"name":"Facility for Anti-Infective Drug Development and Innovation, Victorian College of Pharmacy, Monash University, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger L.","family":"Nation","sequence":"additional","affiliation":[{"name":"Facility for Anti-Infective Drug Development and Innovation, Victorian College of Pharmacy, Monash University, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"552","volume":"23","year":"1964","unstructured":"Barnett, M., S. R. Bushby, and S. Wilkinson. 1964. Sodium sulphomethyl derivatives of polymyxins. Br. J. Pharmacol.23:552-574.","journal-title":"Br. J. Pharmacol."},{"key":"e_1_3_2_3_2","first-page":"119","volume":"31","year":"1982","unstructured":"Bergan, T., and J. Fuglesang. 1982. Polymyxin antibiotics: chemical and pharmacokinetic properties. Antibiot. Chemother.31:119-144.","journal-title":"Antibiot. Chemother."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/62.1.39"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1967.tb01946.x"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0369-8114(03)00040-3"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.2.255"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/srin.2000.20944"},{"key":"e_1_3_2_9_2","unstructured":"Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing; 15th information supplement (M100-S15). Clinical and Laboratory Standards Institute Wayne Pa."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.52.11.987"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(97)00055-0"},{"key":"e_1_3_2_12_2","first-page":"172","volume":"249","year":"1965","unstructured":"Eickhoff, T. C., and M. Finland. 1965. Polymyxin B and colistin: in vitro activity against Pseudomonas aeruginosa. Am. J. Med. Sci.249:172-174.","journal-title":"Am. J. Med. Sci."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.18426"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)61924-4"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(05)70303-5"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhin.2001.0987"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.6.1317"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2911(08)60145-9"},{"key":"e_1_3_2_19_2","unstructured":"Infectious Diseases Society of America. 2004 posting date. Bad bugs no drugs. Infectious Diseases Society of America Alexandria Va. [Online.] http:\/\/www.idsociety.org\/pa\/IDSA_Paper4_final_web.pdf\n."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.119.2_suppl.397S"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/380461"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-72-6-857"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200010000-00014"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0731-7085(89)80201-8"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg468"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.4.1364-1370.2003"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(01)00326-7"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.10.3304-3307.2002"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh167"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.5.1766-1770.2003"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2004.10.001"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.11.4814-4815.2005"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.3.781-785.2001"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1086\/379611"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1053\/rmed.2000.0834"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1086\/338782"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-0691.2004.1004.x"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1080\/07853890310001609"},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","first-page":"R78","DOI":"10.1186\/cc2358","volume":"7","year":"2003","unstructured":"Markou, N., H. Apostolakos, C. Koumoudiou, M. Athanasiou, A. Koutsoukou, I. Alamanos, and L. Gregorakos. 2003. Intravenous colistin in the treatment of sepsis from multiresistant gram-negative bacilli in critically ill patients. Crit. Care7:R78-R83.","journal-title":"Crit. Care"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540410020776-1"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544020-00005"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.54.595"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122010537"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2005.01161.x"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1969.03150240119022"},{"key":"e_1_3_2_46_2","first-page":"41","volume":"7","year":"1959","unstructured":"Schwartz, B. S., M. R. Warren, F. A. Barkley, and L. Landis. 1959. Microbiological and pharmacological studies of colistin sulfate and sodium colistinmethanesulfonate. Antibiot. Annu.7:41-60.","journal-title":"Antibiot. Annu."},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1086\/342570"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.2741\/Tatterso"},{"key":"e_1_3_2_49_2","doi-asserted-by":"crossref","first-page":"N75","DOI":"10.1097\/00003246-200104001-00004","volume":"29","year":"2001","unstructured":"Waterer, G. W., and R. G. Wunderink. 2001. Increasing threat of gram-negative bacteria. Crit. Care Med.29:N75-N81.","journal-title":"Crit. Care Med."},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(97)01266-0"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2005.01076.x"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.1.29"},{"key":"e_1_3_2_53_2","first-page":"8","volume":"27","year":"1974","unstructured":"Yamada, S., T. Mayahara, N. Mitsuhashi, K. Wakabayashi, and K. Hiratsuka. 1974. Colistin sodium methanesulfonate (colimycin, CL-M). I. Blood level, distribution, and excretion of CL-M. Jpn. J. Antibiot.27:8-14.","journal-title":"Jpn. J. Antibiot."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00035-06","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00035-06","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T19:09:02Z","timestamp":1645470542000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00035-06"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["10.1128\/AAC.00035-06"],"URL":"https:\/\/doi.org\/10.1128\/aac.00035-06","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6]]},"assertion":[{"value":"2006-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-03-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}